Accession Number ADA562254
Title Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene in Prostate Cancer Using Liposomal Nanotechnology.
Publication Date Jun 2012
Media Count 11p
Personal Author M. Ittmann
Abstract The TMPRSS2/ERG fusion gene is detected in about 50% of prostate cancer (PCa) patients. It is highly specific for PCa and involved in proliferation and invasion of PCa cells. Some prostate cancers express a single mRNA type, while others express multiple isoforms of the fusion gene that arise via alternative splicing of the initial fusion transcript. The goal of the project is to target the four most common and biologically active alternatively spliced fusion gene transcript isoforms using specifcaly designed siRNAs to obtain maximal biological activity in cancers expressing the particular isoform or a combination of isoforms. Although siRNA offers a powerful tool to silence gene expression of drugable and undrugable targets, in vivo delivery of siRNA remains a great challenge. Therefore development of tumor-specific safe and effective nanodelivery systems is the main goal of the studies for clinical applications of siRNA-therapeutics. We propose to use nanoliposomes encapsulating siRNAs specifically targeting the TMPRSS2/ERG mRNA fusion junctions, to minimize off-target effects in normal tissues so toxicity should be minimal. Our results support the efficacy of this approach.
Keywords Genes
Liposomes
Prostate cancer
Prostate gland
Tissues(Biology)


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57F - Cytology, Genetics, & Molecular Biology
Corporate Author M.D. Anderson Cancer Center, Houston, TX.
Document Type Technical report
Title Note Final rept. 15 May 2009-14 May 2012.
NTIS Issue Number 1224
Contract Number W81XWH-09-1-0385

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader